Trials / Completed
CompletedNCT03186040
Open-label Clinical Trial of Lacosamide in ALS
Open-label Clinical Trial: Safety of Lacosamide in Patients With Amyotrophic Lateral Sclerosis
- Status
- Completed
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 7 (actual)
- Sponsor
- Chiba University · Academic / Other
- Sex
- All
- Age
- 20 Years
- Healthy volunteers
- Not accepted
Summary
Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS).
Detailed description
Lacosamide is administered for patients with amyotrophic lateral sclerosis (ALS). This clinical trial is open-label, single group and before and after comparison study. Dosage of lacosamide is increased from 100mg to 400mg for 4 weeks. Safety of lacosamide administration in ALS is primary endpoint. Nerve excitability, fasciculation and muscle cramp are investigated before and after administration for secondary endpoints.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Lacosamide | Sodium channel blocker |
Timeline
- Start date
- 2017-07-13
- Primary completion
- 2020-04-30
- Completion
- 2020-05-31
- First posted
- 2017-06-14
- Last updated
- 2020-07-15
Locations
1 site across 1 country: Japan
Source: ClinicalTrials.gov record NCT03186040. Inclusion in this directory is not an endorsement.